SoluMatrix® meloxicam demonstrates significant efficacy at 30 percent lower doses

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, will present Phase 3 results that showed osteoarthritis (OA) patients treated...

More...